Literature DB >> 35768649

TRIM36 suppresses cell growth and promotes apoptosis in human esophageal squamous cell carcinoma cells by inhibiting Wnt/β-catenin signaling pathway.

Bin Zhao1, Gaofeng Qiao1, Jianhua Li2, Yukun Wang3, XiaoDong Li1, Hua Zhang4, Lu Zhang5.   

Abstract

Our recent study has shown that TRIM36, a member of tripartite motif-containing (TRIM) family proteins and tumor suppressor and β-catenin may serve as a prognostic biomarker for esophageal squamous cell carcinoma (ESCC). Here, we sought to examine functional roles of TRIM36 and β-catenin in ESCC cells. TRIM36 was overexpressed or silenced by lentivirus transduction. Cell proliferation was examined by Cell Counting Kit (CCK)-8 assay, while cell cycle distribution and cell apoptosis was assessed via flow cytometry analysis. Xenograft mouse model was applied for in vivo analysis. Overexpression of TRIM36 inhibited cell proliferation in human ESCC cells, and silencing of TRIM36 led to opposite effects. We also found that ectopic expression of TRIM36 enhanced the ratio of G0/G1 phase cells and induced apoptosis in ESCC cells. Our data further revealed that TRIM36 stimulated the ubiquitination of β-catenin, and in turn, its inactivation. Finally, we confirmed these in vitro results in a xenograft mouse model and clinical specimens post-operatively obtained from patients of ESCC. In summary, these data support that TRIM36 can effectively inhibit tumorigenesis of ESCC by repressing Wnt/β-catenin signaling pathway, which suggest that selectively repressing this signaling pathway in ESCC may lead to development of a novel therapeutic approach for controlling this disease.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  Apoptosis; Esophageal cancer; TRIM36; Ubiquitination; β-Catenin

Mesh:

Substances:

Year:  2022        PMID: 35768649     DOI: 10.1007/s13577-022-00737-x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  33 in total

Review 1.  Epigenetic biomarkers in esophageal cancer.

Authors:  Andrew M Kaz; William M Grady
Journal:  Cancer Lett       Date:  2012-03-07       Impact factor: 8.679

2.  The Dishevelled-associating protein Daple controls the non-canonical Wnt/Rac pathway and cell motility.

Authors:  Maki Ishida-Takagishi; Atsushi Enomoto; Naoya Asai; Kaori Ushida; Takashi Watanabe; Takahiko Hashimoto; Takuya Kato; Liang Weng; Shinji Matsumoto; Masato Asai; Yoshiki Murakumo; Kozo Kaibuchi; Akira Kikuchi; Masahide Takahashi
Journal:  Nat Commun       Date:  2012-05-29       Impact factor: 14.919

Review 3.  Mitotic and mitogenic Wnt signalling.

Authors:  Christof Niehrs; Sergio P Acebron
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

Review 4.  The complex world of WNT receptor signalling.

Authors:  Christof Niehrs
Journal:  Nat Rev Mol Cell Biol       Date:  2012-11-15       Impact factor: 94.444

Review 5.  Targeted therapy in esophageal cancer.

Authors:  Lei Zhang; Jiaojiao Ma; Yu Han; Jinqiang Liu; Wei Zhou; Liu Hong; Daiming Fan
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-02-19       Impact factor: 3.869

Review 6.  Esophageal cancer: Risk factors, genetic association, and treatment.

Authors:  Fang-Liang Huang; Sheng-Jie Yu
Journal:  Asian J Surg       Date:  2016-12-13       Impact factor: 2.767

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

8.  Global incidence of oesophageal cancer by histological subtype in 2012.

Authors:  Melina Arnold; Isabelle Soerjomataram; Jacques Ferlay; David Forman
Journal:  Gut       Date:  2014-10-15       Impact factor: 23.059

Review 9.  Oesophageal carcinoma.

Authors:  Arjun Pennathur; Michael K Gibson; Blair A Jobe; James D Luketich
Journal:  Lancet       Date:  2013-02-02       Impact factor: 79.321

Review 10.  Advances in targeted therapies and new promising targets in esophageal cancer.

Authors:  Abbes Belkhiri; Wael El-Rifai
Journal:  Oncotarget       Date:  2015-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.